PL2399915T3 - Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy - Google Patents

Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Info

Publication number
PL2399915T3
PL2399915T3 PL11178126T PL11178126T PL2399915T3 PL 2399915 T3 PL2399915 T3 PL 2399915T3 PL 11178126 T PL11178126 T PL 11178126T PL 11178126 T PL11178126 T PL 11178126T PL 2399915 T3 PL2399915 T3 PL 2399915T3
Authority
PL
Poland
Prior art keywords
intermediates
preparation
caspase inhibitors
aspartic
acetal caspase
Prior art date
Application number
PL11178126T
Other languages
English (en)
Inventor
Gerald J Tanoury
Minzhang Chen
Andrew D Jones
Philip L Nyce
Martin Trudeau
David J Guerin
John R Snoonian
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PL2399915T3 publication Critical patent/PL2399915T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
PL11178126T 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy PL2399915T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55248004P 2004-03-12 2004-03-12
EP11178126.6A EP2399915B1 (en) 2004-03-12 2005-03-11 Process and intermediates for the preparation of aspartic acetal caspase inhibitors
EP05728092.7A EP1725548B1 (en) 2004-03-12 2005-03-11 Processes and intermediates for the preparation of aspartic acetal caspase inhibitors

Publications (1)

Publication Number Publication Date
PL2399915T3 true PL2399915T3 (pl) 2015-07-31

Family

ID=34962478

Family Applications (4)

Application Number Title Priority Date Filing Date
PL381358A PL381358A1 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie
PL11178126T PL2399915T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL05728092T PL1725548T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL11178128T PL2399916T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL381358A PL381358A1 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL05728092T PL1725548T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL11178128T PL2399916T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Country Status (22)

Country Link
US (4) US7381827B2 (pl)
EP (3) EP2399916B1 (pl)
JP (2) JP4898658B2 (pl)
KR (2) KR101135765B1 (pl)
CN (3) CN103467459A (pl)
AR (1) AR048008A1 (pl)
AU (1) AU2005223767B2 (pl)
BR (1) BRPI0508609B8 (pl)
CA (3) CA2768700C (pl)
DK (3) DK1725548T3 (pl)
ES (3) ES2533991T3 (pl)
HK (2) HK1105955A1 (pl)
HU (1) HUE024556T2 (pl)
IL (3) IL178003A (pl)
PL (4) PL381358A1 (pl)
PT (3) PT1725548E (pl)
RU (2) RU2433127C2 (pl)
SG (2) SG150546A1 (pl)
SI (3) SI2399916T1 (pl)
TW (3) TW201200508A (pl)
WO (1) WO2005090334A2 (pl)
ZA (1) ZA200607605B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314598A1 (en) 1996-10-18 2011-04-27 Vertex Pharmaceuticals Incorporated Inhibitors of Hepatitis C virus NS3 serine protease
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
CN102161656B (zh) * 2004-02-27 2013-02-20 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
EP1750689A1 (en) * 2004-05-15 2007-02-14 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
BRPI0709567A2 (pt) 2006-03-16 2011-07-12 Vertex Pharma inibidores deuterados de protease de hepatite c
EP2099454A4 (en) * 2006-11-17 2010-11-10 Abbott Lab AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
AU2008219704A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
GEP20125645B (en) * 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
US8518942B2 (en) 2008-08-06 2013-08-27 Buck Institute For Research On Aging Caspase inhibitors and uses thereof
US9113848B2 (en) * 2010-02-03 2015-08-25 Covidien Lp Surgical retrieval apparatus
JP5769655B2 (ja) * 2012-03-30 2015-08-26 ユニ・チャーム株式会社 吸収性物品
CN103193572B (zh) * 2013-04-07 2015-06-17 山东大学 一种拉唑类化合物单一对映体的分离方法
ES2950100T3 (es) 2016-12-23 2023-10-05 Casp Aid Inc Inhibición de la caspasa-1 y usos de esta para la prevención y el tratamiento de afecciones neurológicas

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
BE1008343A3 (nl) 1994-05-06 1996-04-02 Dsm Nv Bidentaat fosfineligand
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
WO1997017286A1 (en) * 1995-11-09 1997-05-15 Akzo-Pq Silica Vof Compacted sodium silicate
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
CA2237314A1 (en) 1996-09-12 1998-03-19 Donald S. Karanewsky Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
WO1998010778A1 (en) 1996-09-12 1998-03-19 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
WO1998011129A1 (en) 1996-09-12 1998-03-19 Idun Pharmaceuticals, Incorporated C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
JP2001508404A (ja) 1996-10-11 2001-06-26 ワーナー―ランバート・コンパニー スルホンアミドインターロイキン―１β変換酵素阻害剤
EP2314598A1 (en) 1996-10-18 2011-04-27 Vertex Pharmaceuticals Incorporated Inhibitors of Hepatitis C virus NS3 serine protease
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
FR2766188B1 (fr) 1997-07-15 2000-02-11 Hoechst Marion Roussel Inc Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
WO1999031066A1 (en) 1997-12-18 1999-06-24 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridones as src family sh2 domain inhibitors
EP1049703B1 (en) 1998-01-20 2003-02-12 Warner-Lambert Company N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl]-l-aspartic acid aldehyde as an in vivo inhibitor of interleukin-1beta converting enzyme
NZ528282A (en) 1998-03-19 2005-05-27 Vertex Pharma Interleukin-1 beta converting enzyme inhibitors
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
ATE336480T1 (de) 1999-03-16 2006-09-15 Cytovia Inc Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
WO2000055127A1 (en) 1999-03-16 2000-09-21 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
BR0009610A (pt) 1999-04-09 2002-02-13 Cytovia Inc Inibidores de caspase e uso dos mesmos
EP1202976B1 (en) 1999-07-19 2006-11-02 Merck Frosst Canada Ltd. Pyrazinones, compositions containing such compounds
WO2001010383A2 (en) 1999-08-06 2001-02-15 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CA2383002A1 (en) 1999-08-27 2001-03-08 Cytovia, Inc. Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
YU73702A (sh) 2000-03-29 2006-03-03 Vertex Pharmaceuticals Incorporated Karbamatni inhibitori kaspaze i njihova upotreba
PT1268519E (pt) 2000-04-03 2005-08-31 Vertex Pharma Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
AU5369201A (en) * 2000-04-24 2001-11-07 Vertex Pharma Process and intermediates for making substituted aspartic acid acetals
TWI291462B (en) 2000-04-25 2007-12-21 Daiichi Sankyo Co Ltd Hydrate crystal of neuraminic acid compound
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
CA2380935A1 (en) 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
DE60131160T2 (de) 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen
US7012066B2 (en) 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
ATE510837T1 (de) 2000-09-13 2011-06-15 Vertex Pharma Caspase inhibitoren und deren verwendung
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
WO2002042278A2 (en) 2000-11-21 2002-05-30 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
CA2443600A1 (en) 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
CA2447999C (en) 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
ES2279879T3 (es) 2001-07-11 2007-09-01 Vertex Pharmaceuticals Incorporated Inhibidores biciclicos puente de la serina proteasa.
AU2002348533A1 (en) 2001-10-09 2003-05-26 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
AU2003225088A1 (en) 2002-04-19 2003-11-03 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
AR040350A1 (es) 2002-06-28 2005-03-30 Vertex Pharma Inhibidores de caspasa y usos de los mismos
CA2511235A1 (en) 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
CN102161656B (zh) * 2004-02-27 2013-02-20 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途

Also Published As

Publication number Publication date
TWI399356B (zh) 2013-06-21
TW201247594A (en) 2012-12-01
BRPI0508609A (pt) 2007-07-31
JP2012072151A (ja) 2012-04-12
KR101135765B1 (ko) 2012-04-23
EP1725548B1 (en) 2015-01-14
EP2399916B1 (en) 2014-12-10
HK1163672A1 (en) 2012-09-14
IL178003A0 (en) 2006-12-31
CN103467459A (zh) 2013-12-25
EP2399915A1 (en) 2011-12-28
CA2559303A1 (en) 2005-09-29
US20110071298A1 (en) 2011-03-24
US20060020016A1 (en) 2006-01-26
KR20110137409A (ko) 2011-12-22
SG150547A1 (en) 2009-03-30
CA2843066C (en) 2016-06-07
RU2011127174A (ru) 2013-01-10
TW201200508A (en) 2012-01-01
IL218487A (en) 2015-08-31
PT2399916E (pt) 2015-03-17
TW200602341A (en) 2006-01-16
HK1105955A1 (en) 2008-02-29
CA2768700C (en) 2014-04-29
AR048008A1 (es) 2006-03-15
AU2005223767A1 (en) 2005-09-29
CA2559303C (en) 2013-09-10
CA2768700A1 (en) 2005-09-29
RU2006136032A (ru) 2008-04-20
US20130066083A1 (en) 2013-03-14
SG150546A1 (en) 2009-03-30
PL381358A1 (pl) 2007-05-28
JP2007528904A (ja) 2007-10-18
RU2433127C2 (ru) 2011-11-10
TWI398426B (zh) 2013-06-11
PL1725548T3 (pl) 2015-08-31
CN1950364B (zh) 2011-06-08
HUE024556T2 (hu) 2016-02-29
ES2532967T3 (es) 2015-04-06
US8293929B2 (en) 2012-10-23
EP2399916A1 (en) 2011-12-28
CN1950364A (zh) 2007-04-18
US20090048429A1 (en) 2009-02-19
CA2843066A1 (en) 2005-09-29
WO2005090334A2 (en) 2005-09-29
SI2399916T1 (sl) 2015-05-29
WO2005090334A3 (en) 2005-11-17
EP2399915B1 (en) 2014-12-17
KR20070006835A (ko) 2007-01-11
US7834200B2 (en) 2010-11-16
IL178003A (en) 2012-04-30
DK1725548T3 (en) 2015-03-23
US7381827B2 (en) 2008-06-03
ES2532433T3 (es) 2015-03-26
SI2399915T1 (sl) 2015-05-29
SI1725548T1 (sl) 2015-05-29
BRPI0508609B8 (pt) 2021-05-25
AU2005223767B2 (en) 2011-12-01
BRPI0508609B1 (pt) 2021-03-30
CN102225936A (zh) 2011-10-26
ES2533991T3 (es) 2015-04-16
IL218487A0 (en) 2012-04-30
JP4898658B2 (ja) 2012-03-21
CN102225936B (zh) 2013-09-11
DK2399916T3 (en) 2015-03-02
PT1725548E (pt) 2015-04-16
PL2399916T3 (pl) 2015-06-30
DK2399915T3 (en) 2015-03-09
IL218488A0 (en) 2012-04-30
ZA200607605B (en) 2009-04-29
PT2399915E (pt) 2015-03-30
EP1725548A2 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
PL2399915T3 (pl) Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
ITMI20032121A1 (it) Procedimento per la preparazione di imiquimod e suoi intermedi
GB2428296B (en) Enhancing the acqisition and processing of low frequencies for sub-salt imaging
IL187303A0 (en) Methods of prepering 3 - cyano - quinolines and intermediates made thereby
TWI371215B (en) Acoustic device & method of making acoustic device
EP1753708A4 (en) NEW SIRTUIN ACTIVATING COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
ZA200702836B (en) Diaminoalkane aspartic protease inhibitors
ZA200711085B (en) Processes for the manufacture of rosuvastatin and intermediates
TWI367257B (en) Process for the preparation of 2-butanol
EP1856006A4 (en) SIALON CERAMIC AND METHOD OF MANUFACTURE
IL190201A0 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
EP1951278A4 (en) METHODS AND COMPOSITIONS FOR DEREPRESSION OF IPA-INHIBITED CASPASE
EP1979289A4 (en) CERAMIC MATERIALS AND METHODS OF MAKING AND USING THE SAME
EP1720563A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
PL1937626T3 (pl) Sposób i związki do otrzymywania salmeterolu
EP1853559A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF ATORVASTATIN AND INTERMEDIATES THEREOF
EP1862078A4 (en) CHOCOLATE AND METHOD OF MANUFACTURING THE SAME
IL187832A0 (en) Methods and intermediates for the preparation of optionally radio- labeled imatinib
SG115828A1 (en) Fluid-ejection device and methods of forming same
GB0504333D0 (en) Treatment of cytokine dysregulation
PL1721965T3 (pl) Sposób wytwarzania i zastosowanie kultur pierwotniaków
GB0427501D0 (en) Method of casting an article
HK1101078A1 (en) Process for the preparation of tryptase inhibitors
ZA200802668B (en) PDE inhibitors and combinations thereof for the treatment of urological disorders
GB0409178D0 (en) Method of cleaning